Sunshine Heart rallies as Thoratec falls

|About: Sunshine Heart, Inc. (SSH)|By:, SA News Editor

Sunshine Heart (SSH) moves 2.7% higher in premarket trading.

Investors are likely reacting to the NEJM and JHLT manuscripts which warn of device exchanges linked to thrombus occurring with HeartMate II (THOR) devices.

SSH's C-Pulse system treats clinical symptoms associated with Class III and ambulatory Class IV heart failure.

THOR is now -10% premarket

For more on the journal manuscripts, THOR, and HTWR, see here and here